310 related articles for article (PubMed ID: 24582529)
1. To acquire or resist: the complex biological effects of CRISPR-Cas systems.
Bondy-Denomy J; Davidson AR
Trends Microbiol; 2014 Apr; 22(4):218-25. PubMed ID: 24582529
[TBL] [Abstract][Full Text] [Related]
2. Role of CRISPR/cas system in the development of bacteriophage resistance.
Szczepankowska A
Adv Virus Res; 2012; 82():289-338. PubMed ID: 22420856
[TBL] [Abstract][Full Text] [Related]
3. Adaptation in CRISPR-Cas Systems.
Sternberg SH; Richter H; Charpentier E; Qimron U
Mol Cell; 2016 Mar; 61(6):797-808. PubMed ID: 26949040
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas, a prokaryotic adaptive immune system, in endodontic, oral, and multidrug-resistant hospital-acquired Enterococcus faecalis.
Burley KM; Sedgley CM
J Endod; 2012 Nov; 38(11):1511-5. PubMed ID: 23063226
[TBL] [Abstract][Full Text] [Related]
5. Adaptation in bacterial CRISPR-Cas immunity can be driven by defective phages.
Hynes AP; Villion M; Moineau S
Nat Commun; 2014 Jul; 5():4399. PubMed ID: 25056268
[TBL] [Abstract][Full Text] [Related]
6. CRISPR adaptation in Escherichia coli subtypeI-E system.
Kiro R; Goren MG; Yosef I; Qimron U
Biochem Soc Trans; 2013 Dec; 41(6):1412-5. PubMed ID: 24256229
[TBL] [Abstract][Full Text] [Related]
7. The CRISPR-Cas Immune System and Genetic Transfers: Reaching an Equilibrium.
Samson JE; Magadan AH; Moineau S
Microbiol Spectr; 2015 Feb; 3(1):PLAS-0034-2014. PubMed ID: 26104549
[TBL] [Abstract][Full Text] [Related]
8. The roles of CRISPR-Cas systems in adaptive immunity and beyond.
Barrangou R
Curr Opin Immunol; 2015 Feb; 32():36-41. PubMed ID: 25574773
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas and restriction-modification systems are compatible and increase phage resistance.
Dupuis MÈ; Villion M; Magadán AH; Moineau S
Nat Commun; 2013; 4():2087. PubMed ID: 23820428
[TBL] [Abstract][Full Text] [Related]
10. Occurrence and Diversity of CRISPR-Cas Systems in the Genus Bifidobacterium.
Briner AE; Lugli GA; Milani C; Duranti S; Turroni F; Gueimonde M; Margolles A; van Sinderen D; Ventura M; Barrangou R
PLoS One; 2015; 10(7):e0133661. PubMed ID: 26230606
[TBL] [Abstract][Full Text] [Related]
11. CRISPR-Cas Systems in Prokaryotes.
Burmistrz M; Pyrć K
Pol J Microbiol; 2015; 64(3):193-202. PubMed ID: 26638527
[TBL] [Abstract][Full Text] [Related]
12. Structural plasticity and in vivo activity of Cas1 from the type I-F CRISPR-Cas system.
Wilkinson ME; Nakatani Y; Staals RH; Kieper SN; Opel-Reading HK; McKenzie RE; Fineran PC; Krause KL
Biochem J; 2016 Apr; 473(8):1063-72. PubMed ID: 26929403
[TBL] [Abstract][Full Text] [Related]
13. Clustered regularly interspaced short palindromic repeats (CRISPRs): the hallmark of an ingenious antiviral defense mechanism in prokaryotes.
Al-Attar S; Westra ER; van der Oost J; Brouns SJ
Biol Chem; 2011 Apr; 392(4):277-89. PubMed ID: 21294681
[TBL] [Abstract][Full Text] [Related]
14. Gene regulation by engineered CRISPR-Cas systems.
Fineran PC; Dy RL
Curr Opin Microbiol; 2014 Apr; 18():83-9. PubMed ID: 24637219
[TBL] [Abstract][Full Text] [Related]
15. [Advances in molecular mechanisms of adaptive immunity mediated by type I-E CRISPR/Cas system--A review].
Sun D; Qiu J
Wei Sheng Wu Xue Bao; 2016 Jan; 56(1):1-7. PubMed ID: 27305774
[TBL] [Abstract][Full Text] [Related]
16. Diversity, evolution, and therapeutic applications of small RNAs in prokaryotic and eukaryotic immune systems.
Cooper EL; Overstreet N
Phys Life Rev; 2014 Mar; 11(1):113-34. PubMed ID: 24286719
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of E. coli CRISPR-cas promoters and their silencing by H-NS.
Pul U; Wurm R; Arslan Z; Geissen R; Hofmann N; Wagner R
Mol Microbiol; 2010 Mar; 75(6):1495-512. PubMed ID: 20132443
[TBL] [Abstract][Full Text] [Related]
18. The subtype I-F CRISPR-Cas system influences pathogenicity island retention in Pectobacterium atrosepticum via crRNA generation and Csy complex formation.
Richter C; Fineran PC
Biochem Soc Trans; 2013 Dec; 41(6):1468-74. PubMed ID: 24256239
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas systems and RNA-guided interference.
Barrangou R
Wiley Interdiscip Rev RNA; 2013; 4(3):267-78. PubMed ID: 23520078
[TBL] [Abstract][Full Text] [Related]
20. Requirements for a successful defence reaction by the CRISPR-Cas subtype I-B system.
Stoll B; Maier LK; Lange SJ; Brendel J; Fischer S; Backofen R; Marchfelder A
Biochem Soc Trans; 2013 Dec; 41(6):1444-8. PubMed ID: 24256235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
